Annovis Bio, Inc. (ANVS): Submission of Matters to a Vote of Security Holders
Annovis Bio, Inc. (ANVS) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001477845 0001477845 2026-06-17 2026-06-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report
How this was made
The 30-second read
Why it matters
The only potentially tradable element is stockholder approval of amendments to the 2019 Equity Incentive Plan, increasing the share authorization and annual award cap; other items are director election and non-binding executive comp frequency votes.
Market read
Shareholder approvals are typically low-volatility, but the expanded equity plan authorization can influence dilution expectations and future compensation-driven share issuance.
What to watch
Traders may want to cross-check the related April 30, 2026 definitive proxy for context on expected hiring/compensation plans, since the 8-K itself is only the vote recap.
Background
This SEC 8-K reports Item 5.07: final voting results from Annovis Bio’s June 17, 2026 virtual annual meeting.
Ticker impact
Annovis Bio reported 2026 annual meeting voting results, including approval of an equity plan share increase and director elections.
Likely limited near-term impact; any effect would be indirect via dilution expectations from the expanded equity plan.
The filing discloses final vote tallies and approval of an equity incentive plan amendment (share pool increase), but provides no new financial guidance, clinical, or regulatory catalyst.
Market effects
Minimal; this is company-specific governance and equity-plan capacity rather than a sector-wide regulatory or clinical development.
Minimal; no cross-border transaction or macro policy change is disclosed.
Low; no international deal, partnership, or global regulatory action is mentioned.
Counterpoint
The equity plan share increase could be viewed as a dilution overhang, but the article provides no details on actual grants or near-term financing needs.
Key entities
- companyAnnovis Bio, Inc.
Subject of the 8-K; reported annual meeting voting results and approval of equity plan amendments.
- auditorErnst & Young LLP
Stockholders ratified the appointment of the independent auditors.
